{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:34Z","timestamp":1788391174498,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.017","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"765-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings"],"prefix":"10.1016","volume":"40","author":[{"given":"Daisuke","family":"Nishizaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez N.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.hoc.2026.05.017_bib1","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.hoc.2026.05.017_bib2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/bjs.10572","article-title":"Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases","volume":"104","author":"Zhao","year":"2017","journal-title":"Br J Surg"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.017_bib4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.017_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.017_bib6","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.017_bib7","doi-asserted-by":"crossref","first-page":"S1408","DOI":"10.1016\/j.annonc.2022.08.039","article-title":"LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2026.05.017_bib8","first-page":"1","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.017_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterology & hepatology"},{"key":"10.1016\/j.hoc.2026.05.017_bib10","unstructured":"National Cancer Institute. Targeted Therapy to Treat Cancer. https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapieshttps:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies. Accessed May 16, 2023."},{"issue":"1","key":"10.1016\/j.hoc.2026.05.017_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamasurg.2013.3172","article-title":"Venous thromboembolism after major cancer surgery: temporal trends and patterns of care","volume":"149","author":"Trinh","year":"2014","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.017_bib12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.surg.2018.05.028","article-title":"Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials","volume":"164","author":"Rausa","year":"2018","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.017_bib13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2006-10-053736","article-title":"Trousseau\u2019s syndrome: multiple definitions and multiple mechanisms","volume":"110","author":"Varki","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2026.05.017_bib14","first-page":"e072715","article-title":"Prevention of venous thromboembolism in patients with cancer","volume":"381","author":"Guntupalli","year":"2023","journal-title":"BMJ (Clinical research ed)"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.017_bib15","first-page":"221","article-title":"Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Alahmari","year":"2016","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib16","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/jcm9082664","article-title":"Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab","volume":"9","author":"Ngo","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.017_bib17","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib18","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-12-2911","article-title":"Aflibercept","volume":"19","author":"Ciombor","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.hoc.2026.05.017_bib19","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.017_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.017_bib21","first-page":"Cd004318","article-title":"Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery","volume":"11","author":"Felder","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.017_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/ALN.0b013e3182a4441f","article-title":"Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery","volume":"120","author":"Glance","year":"2014","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.017_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bja.2018.09.010","article-title":"Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies","volume":"122","author":"Nagrebetsky","year":"2019","journal-title":"Br J Anaesth"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.017_bib24","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1080\/10428194.2017.1296145","article-title":"Surgical treatment of acute abdominal complications in hematology patients: outcomes and prognostic factors","volume":"58","author":"Mokart","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.017_bib25","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"10106","key":"10.1016\/j.hoc.2026.05.017_bib26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.017_bib27","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.017_bib28","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.017_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajco.12636","article-title":"Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer","volume":"12","author":"Friedlander","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.017_bib30","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jcph.1938","article-title":"Risk of thrombocytopenia with platelet-derived growth factor receptor kinase inhibitors in cancer patients: a systematic review and meta-analysis of phase 2\/3 randomized, controlled trials","volume":"61","author":"Liu","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.017_bib32","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.hoc.2026.05.017_bib33","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.18632\/oncotarget.10019","article-title":"Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib34","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15354","article-title":"Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy","volume":"19","author":"Watson","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.017_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.34495","article-title":"Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II\/III trial of the German AIO and Italian GOIM","volume":"153","author":"Goetze","year":"2023","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.017_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.017_bib37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2026.05.017_bib38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","article-title":"NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors","volume":"8","author":"Demetri","year":"2010","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9440","key":"10.1016\/j.hoc.2026.05.017_bib39","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.hoc.2026.05.017_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.017_bib41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.017_bib42","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.017_bib43","first-page":"Cd007930","article-title":"Angiogenesis inhibitors for the treatment of epithelial ovarian cancer","volume":"4","author":"Gaitskell","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.017_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.017_bib45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/DCR.0000000000000966","article-title":"A population-based study of complications after colorectal surgery in patients who have received bevacizumab","volume":"61","author":"Baxter","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.017_bib46","doi-asserted-by":"crossref","first-page":"e0243252","DOI":"10.1371\/journal.pone.0243252","article-title":"Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"15","author":"King","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib47","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/cancers15082264","article-title":"Safety of early bevacizumab administration after central venous port placement for patients with colorectal cancer","volume":"15","author":"Shigyo","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.017_bib48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.14309\/ajg.0000000000002149","article-title":"Effect of biologics on the risk of advanced-stage inflammatory bowel disease-associated intestinal cancer: a nationwide study","volume":"118","author":"Seishima","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.017_bib49","doi-asserted-by":"crossref","first-page":"e171538","DOI":"10.1001\/jamasurg.2017.1538","article-title":"Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis","volume":"152","author":"Kulaylat","year":"2017","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.017_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crohns.2013.01.014","article-title":"Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis","volume":"7","author":"Billioud","year":"2013","journal-title":"Journal of Crohn\u2019s & Colitis"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.017_bib51","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/keab438","article-title":"Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept","volume":"61","author":"Rempenault","year":"2022","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.017_bib52","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.017_bib53","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.017_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.hoc.2026.05.017_bib55","unstructured":"National Comprehensive Cancer Network (NCCN). Gastrointeoinal Stromal Tumors (Version 1. 2023). 2023; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gist.pdf. Accessed August 7, 2023."},{"issue":"10298","key":"10.1016\/j.hoc.2026.05.017_bib56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(21)00766-2","article-title":"Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial","volume":"398","author":"Moss","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.017_bib57","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10147-015-0830-7","article-title":"Is there any effect of first-day usage of a totally implantable venous access device on complications?","volume":"20","author":"Karanlik","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.017_bib58","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ejso.2011.06.016","article-title":"Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre","volume":"37","author":"Narducci","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.017_bib59","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejso.2016.10.020","volume":"43","author":"Kakkos","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.017_bib60","doi-asserted-by":"crossref","first-page":"e001282","DOI":"10.1136\/jitc-2020-001282","article-title":"Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer","volume":"8","author":"Reuss","year":"2020","journal-title":"Journal for immunotherapy of Cancer"},{"key":"10.1016\/j.hoc.2026.05.017_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.017_bib62","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.017_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.017_bib64","doi-asserted-by":"crossref","first-page":"e1864","DOI":"10.1634\/theoncologist.2020-0681","article-title":"Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer","volume":"25","author":"Karasic","year":"2020","journal-title":"Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.017_bib65","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1080\/17512433.2022.2121704","article-title":"Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials","volume":"15","author":"Liu","year":"2022","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:00:48Z","timestamp":1788390048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000596"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.017","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}